Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H17N3O3 |
| Molecular Weight | 311.3352 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=NN(C(=N1)C2=CC=C(OC)C=C2)C3=CC=C(OC)C=C3
InChI
InChIKey=OBAICMYWONZOSZ-UHFFFAOYSA-N
InChI=1S/C17H17N3O3/c1-21-14-8-4-12(5-9-14)16-18-17(23-3)19-20(16)13-6-10-15(22-2)11-7-13/h4-11H,1-3H3
| Molecular Formula | C17H17N3O3 |
| Molecular Weight | 311.3352 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:27:12 GMT 2025
by
admin
on
Mon Mar 31 23:27:12 GMT 2025
|
| Record UNII |
LN4A42V962
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9922739
Created by
admin on Mon Mar 31 23:27:12 GMT 2025 , Edited by admin on Mon Mar 31 23:27:12 GMT 2025
|
PRIMARY | |||
|
LN4A42V962
Created by
admin on Mon Mar 31 23:27:12 GMT 2025 , Edited by admin on Mon Mar 31 23:27:12 GMT 2025
|
PRIMARY | |||
|
524699-72-7
Created by
admin on Mon Mar 31 23:27:12 GMT 2025 , Edited by admin on Mon Mar 31 23:27:12 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Class: Antiplatelet, Small molecule; Mechanism of Action: Cyclo-oxygenase 1 inhibitor; Highest Development Phase: No development reported for Pain, Rheumatoid arthritis or Thrombosis; Most Recent Events: 08 Oct 2001 No-Development-Reported for Pain in Japan (PO), 15 May 2000 A study has been added to the Pain Control pharmacodynamics section
|
||
|
ACTIVE MOIETY |
The IC50 ratios of rhCOX-2 to rhCOX-1 for ASP6537 and aspirin were > 142,000 and 1.63 fold, respectively. ASP6537 inhibited TXA2 production more selectively than aspirin in in vitro and in vivo TXA2/PGI2 production studies. ASP6537 exerted a significant antithrombotic effect at 3 mg/kg, while aspirin tended to inhibit thrombosis at 300 mg/kg but it was not statistically significant. Further, ASP6537 did not induce ulcer formation at 100 mg/kg, whereas aspirin exhibited an ulcerogenic effect at doses of 100 mg/kg. ASP6537 functions as a highly selective COX-1 inhibitor with a superior ability to aspirin for normalizing TXA2/PGI2 balance, and exerts antithrombotic effect without ulcerogenic effect.
|
